» Articles » PMID: 23449549

Effects of Bezafibrate Treatment in a Patient and a Carrier with Mutations in the PNPLA2 Gene, Causing Neutral Lipid Storage Disease with Myopathy

Citing Articles

Two PNPLA2 heterozygous mutations result in neutral lipid storage disease with myopathy: a case report.

Yang T, Zhu J, Kang Y, Tang C, Zhang L, Guo L BMC Musculoskelet Disord. 2024; 25(1):661.

PMID: 39174932 PMC: 11342685. DOI: 10.1186/s12891-024-07772-9.


Hormone-sensitive lipase protects adipose triglyceride lipase-deficient mice from lethal lipotoxic cardiomyopathy.

Yamada M, Suzuki J, Sato S, Zenimaru Y, Saito R, Konoshita T J Lipid Res. 2022; 63(5):100194.

PMID: 35283217 PMC: 9062333. DOI: 10.1016/j.jlr.2022.100194.


Neutral Lipid Storage Disease Associated with the PNPLA2 Gene: Case Report and Literature Review.

Samukawa M, Nakamura N, Hirano M, Morikawa M, Sakata H, Nishino I Eur Neurol. 2020; 83(3):317-322.

PMID: 32564019 PMC: 7592920. DOI: 10.1159/000508346.


Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence.

Cheng H, Tan W, Low Z, Marvalim C, Lee J, Tan N Int J Mol Sci. 2019; 20(20).

PMID: 31614690 PMC: 6834327. DOI: 10.3390/ijms20205055.


Metabolic lipid muscle disorders: biomarkers and treatment.

Angelini C, Pennisi E, Missaglia S, Tavian D Ther Adv Neurol Disord. 2019; 12:1756286419843359.

PMID: 31040882 PMC: 6477769. DOI: 10.1177/1756286419843359.